Michaela D. Gjerstad
Guido Alves1,2,3
Jodi Maple-Grødem- 1The Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger, Norway
- 2Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, Stavanger, Norway
- 3Department of Neurology, Stavanger University Hospital, Stavanger, Norway
Sleep contributes to the consolidation of our memory and facilitates learning. Short term sleep deprivation temporarily reduces mnestic capacity, whereas long lasting sleep deprivation is associated with structural changes in the hippocampus and cortical areas. However, it is unknown whether early intervention and treatment of sleep disorders could have a neuroprotective effect. In neurodegenerative diseases sleep disorders can occur at preclinical stages and are frequently observed in patients with established Parkinson's disease (PD) and other α-synucleinopathies. REM sleep behavior disorder (RBD) is recognized as a hallmark for the development of α-synucleinopathies and may predict early cognitive decline, while excessive daytime sleepiness (EDS) is present in 12% of patients with PD before treatment initiation and increases continuously over time, causing substantial restrictions for the patients' social life. In more advanced disease, EDS is associated with dementia. Even though well recognized, limited attention has been given to genetics or the treatment of RBD and EDS in early PD. Systematic screening and early intervention can be expected to increase the patients' quality of life, but it remains unclear if this will also impact disease progression. Intervention studies in preclinical and early stages of α-synucleinopathies are needed to increase our understanding of the underlying pathomechanisms and may also provide important inroads to help clarify whether sleep disturbances are secondary to the neurodegenerative process or also contribute to disease exacerbation.
Introduction
The wish for restorative sleep is equal for any human. Close to one third of the human life is spent asleep and perfect sleep means awakening refreshed and oblivious to the hours spent at rest. A number of conditions have to be satisfied in order to sleep well. These include the duration, continuity, rhythmicity, quality, and amount of time spent in different sleep stages. Short term sleep disruption can temporarily impede most behavioral processes (1) and lead to deficits in attention, executive function, non-declarative and declarative memory, and emotional reactivity and sensory perception (2, 3). Conversely, a good night's sleep or daytime napping has significant beneficial effects on human alertness and experienced well-being (4, 5), and the synaptic homeostasis hypothesis indicates sleep as the essential phase to facilitate plasticity of the brain and memory consolidation, by reducing the burden of plasticity on neurons while restoring neuronal selectivity and the ability to learn (6). The complexity of our sleep/wake system makes sleep vulnerable to disturbances, which then can lead to adverse health outcomes.
Sleep quality and duration change with aging (7). The increasingly disturbed sleep in the elderly is caused by a weakening of the circadian system with a blunted diurnal melatonin level (8), as well as, changes in the sleep and wake regulating systems (9). Reciprocally, weakened sleep structures render the patient prone to the development of sleep disturbances and subsequently reduced daytime function. Other reasons for sleep disorders in the elderly may be the occurrence of diseases causing sleep disruption or medication.
It remains unclear to what extent disturbances of sleep caused by aging or disease contribute to the development of neurodegenerative diseases or whether they are only a byproduct of other conditions. Further, it is unknown if early intervention to treat sleep disturbances may delay the neurodegenerative processes. This viewpoint will address these matters, focusing on two major sleep disorders: Excessive daytime sleepiness (EDS) and REM sleep behavior disorder (RBD). EDS and RBD occur frequently in early α-synucleinopathies and have possible implications for further disease development. Early detection and intervention may clarify parts of the riddle as to what extent sleep disturbances contribute to the cause or the consequence of PD. Finally, sleep deprivation will be shortly discussed as increasing evidence indicates that this may also be a key player in these neurodegenerative diseases.
Early Parkinson's Disease and Sleep Disorders
Disturbed or impaired sleep is very common in PD. The most frequent sleep disturbances recorded in PD are EDS, RBD and insomnia. The pathogenesis of these sleep disturbances may be attributed to the underlying disease pathologies involving the brainstem and the hypothalamus, or be the consequence of indirect mechanisms, for example dopaminergic medication or PD-related motor and non-motor symptoms (10–12). EDS is typically more prevalent in later stages of the disease, whilst RBD may be present years before the classic clinical features of PD and other α-synucleinopathies such as dementia with Lewy bodies occur (13).
Several subtypes of PD exist: While age of onset (14) and motor-subtype (15) have long been recognized as important prognostic factors for the course of PD, certain non-motor patterns are now also considered to indicate different neuropathological pathways and progression rates (16). Sleep phenotypes observed in PD are proposed to be associated with specific patterns of pathological progression, which can have subsequent impact on clinical presentations. For example, the brainstem-dominant phenotype is reported to relate to non-motor symptoms, such as olfactory disturbances and psychiatric symptoms (17). These findings remain debated but may be useful to indicate prognosis or treatment response, and more studies of the natural history of sleep disturbances and disease progression from premotor- and early motor-stages of disease will help to clarify if sleep symptoms help to define specific PD subtypes.
RBD in Early PD
RBD is a parasomnia triggered by lower brainstem dysfunction, resulting in lack of physiological atonia during REM sleep (18). Consequently, patients may enact their dreams physically or vocally during REM sleep (19). RBD is a major risk factor for the development of α-synucleinopathies, occurring in 20–75% of patients (20, 21). It has been associated with more severe motor symptoms and signs, and more depression/anxiety (16), and was found to be one of the strongest clinical predictors of cognitive impairment after older age (22).
RBD is accepted as a risk marker and in the context of research is increasingly used to estimate likelihood ratios of developing PD. Patients with incident RBD without Parkinsonism will on average be diagnosed with an α-synucleinopathy within a decade of the onset of the sleep disorder (23). The emergence of RBD can be attributed to the initial α-synuclein pathology associated dysfunction in the brainstem, which later ascends to more rostral structures. The motor symptoms only manifest after the loss of about 80% of the substantia nigra cells (24, 25). Furthermore, a PET study detected microglial activation in the substantia nigra of patients with idiopathic RBD (26), implicating neuroinflammation in the early stages of α-synucleinopathies.
Not all patients with PD will display clinically relevant RBD, indicating that additional factors are involved in the co-occurrence of RBD and PD. Several genetic variants have been identified, which in addition to influencing susceptibility for PD, may also affect the risk of developing RBD. Among these are pathogenic variants in GBA, the gene encoding for the enzyme Glucocerebrosidase, which are associated with idiopathic RBD and worsening of the frequency of symptoms of RBD over time in both the non-PD population (27, 28) and in PD patients (27, 29–31). RBD also preceded the onset of the cardinal motor symptoms of PD SNCA p.A53T carriers (32), although the association of RBD with more common PD-risk SNCA variants is inconclusive (33–35). In contrast, polymorphism in SCARB2 and MAPT have been associated with a reduced risk of developing PD or RBD in the non-PD population (33, 36). Combining genetic and clinical sleep data may assist in identifying individuals susceptible to PD in the prodromal phase, and in doing so offer an important window of time for neuroprotective treatment or lifestyle interventions.
EDS in Early PD
EDS in PD is defined as an inappropriate increased sleep propensity or increased need of time spent asleep, and is most frequently measured with the Epworth Sleepiness Scale (positive if score >10) (37). EDS causes frequent, major social problems and may interfere with the patients' driving abilities. The increase in frequency of EDS with disease duration and severity may be explained by an advancing neurodegenerative process. Other causes for EDS in PD are the potential sedating effect of dopaminergic medication, as well as secondary increased sleep propensity during daytime due to dysregulated and insufficient night time sleep (38).
Occurrence of EDS in the general population has been associated with the development of dementia and especially AD (39, 40). It remains uncertain to what extent EDS may precede the development of Parkinsonism and whether the occurrence of EDS in early PD foretells a certain disease progression. The only two studies to examine EDS longitudinally in the general population report a higher risk for the subsequent development of PD (41, 42). In our population based incident cohort study, drug naïve patients with PD reported more frequent EDS compared to age and sex matched controls, and an increased Epworth Sleepiness Scale score at baseline was found to be the main risk for the subsequent development of EDS (43). Nevertheless, results remain contrary, with findings of both increased and equivalent prevalence of EDS compared to matched healthy control subjects (44, 45). To avoid the confounding influence of dopaminergic treatment on sleepiness more longitudinal population studies are needed, examining drug naive patients and the role of EDS as a prodromal or associated feature in early PD.
There are no proven genetic risk factors for EDS in PD. Several studies have investigated a link between EDS and the Catechol O-methyltransferase (COMT) val158met polymorphism, which affects synaptic dopamine levels following neurotransmitter release, but the results are inconsistent (46, 47). Interestingly, in the Sleep Heart Health Study, daytime sleepiness was found to be associated with an intronic variant in the gene encoding phosphodiesterase 4D (PDE4D) (48). PDE4D is implicated in memory consolidation, one of the functions of sleep, and might represent a therapeutic target for cognition enhancement. Furthermore, in PD, PDE4D is significantly hypermethylated compared to controls (49), and PDE4 inhibitors have been shown to have a neuroprotective effect in mice treated with MPTP (50), whilst broad spectrum PDE inhibitors protect cultured neurons against amyloid-beta (Aβ) and α- synuclein-induced synapse damage (51).
Lessons From Other Fields: The Role of Sleep Deprivation
Mounting evidence points to short- or long-term sleep deprivation as a cause to structural and pathological changes in the brain. A number of animal studies document the sensitivity of the hippocampus to chronic sleep deprivation (52) and an imaging study reported increased neuronal loss in the hippocampus of patients with chronic insomnia (53). In mice, sleep deprivation promotes astrocytic phagocytosis and microglial activation (54), likely leading to exacerbated phagocytosis of synaptic elements.
Several studies also show that sleep is the most important diurnal phase for clearance of neuronal metabolites such as Aβ42 (55–57). In addition, the reduction of slow wave sleep increase the level of brain Aβ prior to amyloid deposition, the hallmark of Alzheimer's disease (AD), which is also observed in patients with dementia with Lewy bodies (DLB) and PD (58), indicating that interventions targeting sleep that reduce amyloid burden could be of significance in the prevention or treatment of both AD and α-synucleinopathies.
Genetic Influences on Sleep: Clues for Intervention Strategies
Healthy people vary in their preferences for sleep timing and length, and response to sleep deprivation and susceptibility to sleep disorders varies from person to person. Although environmental factors can account for much of this variability, an individual's underlying genetic architecture (including genetic mutations and polymorphisms, and epigenetic changes) undoubtedly influences sleep. As discussed, relatively little is known about the role of genetic variants in sleep-related disorders in α-synucleinopathies, but recent advances in the study of circadian genes and epigenetics in other fields suggests possible targets for intervention therapies.
Sleeping and waking outside of the times set by the internal circadian clock can cause negative health outcomes, including neurological issues. In the general population, mistimed sleep, like that associated with jet lag or shift work, disrupts the rhythms of hundreds of genes, including key regulators of gene expression and core clock genes, notably CLOCK and ARNTL (BMAL1) (59). Interestingly, the phase and amplitude of the clock genes may also be altered in PD (60–62), proposing that sleep dysfunction seen in early PD may reflect an underlying pathology in the molecular clock. The molecular mechanisms that disrupt circadian regulation in PD are not clear, however patients with α-synucleinopathies exhibit DNA methylation changes associated with clock genes, for example decreased methylation of the NPAS2 gene promoter from PD patients (63) and of PER1 and CRY1 from DLB patients (64) leukocytes have been reported. Although effects on the central circadian clock have not been shown, aberrant DNA methylation of key clock genes in the PD brain may potentiate widespread circadian deregulation and the development of sleep disorders and/or PD. Alternative theories point to the role of progressive dopaminergic loss within the nigrostriatal system, since dopamine both regulates and is regulated by the clock genes in the hypothalamic suprachiasmatic nucleus and peripheral brain areas (65, 66).
The association between dopaminergic therapies and circadian genetic markers in PD has not been investigated, but animal models have demonstrated increased mRNA levels of selected clock genes after application of D1 and D2 dopamine receptor agonists (67), while D2 dopamine antagonists blunted the rhythm of striatal PER2 (68). These observations have implications for circadian abnormalities seen in PD, especially in medicated patients or in advanced disease.
Discussion
Sleep problems are among the earliest symptoms of PD and increase with disease progression. RBD and EDS are the most common documented disorders affecting the patient, whereas research on disruption of the circadian system is just at the beginnings. It is not yet known if early treatment of sleep disorders could reduce the risk of developing α-synucleinopathies or slow disease progression, but as our understanding of the restorative role that sleep plays increases (6), the suggestion that interventions targeting sleep disorders will have positive implications for α-synucleinopathy disease susceptibility and progression gains credence.
To date there is limited evidence that behavioral or pharmaceutical interventions to regularize sleep/wake activity might be therapeutically useful in neurodegenerative disease. As in humans, sleep deprivation in mice can cause degeneration of neurons. Mouse models of Huntington's disease (HD) display degeneration of sleep rhythms, and early pharmacological intervention to restore sleep by treatment with the sedative clonazepam at the onset of the light phase, normalizes clock gene oscillation in these mice and significantly improves cognitive performance in this model (69). More recently, the motor symptoms of the HD mice were also alleviated following early time-restricted feeding intervention that improved circadian rhythmicity (70). These observations give hope that treatments or lifestyle interventions aimed at restoring circadian rhythms are promising targets to slow the neurodegenerative processes and could also improve other circadian gene-regulated functions that are impaired in PD.
Sleep disturbances, especially insomnia, in young adults seem to have the potential to cause structural changes of the brain. To what extent this may have health consequences decades later one can only speculate. A recent published Nordic study reports a 1.24 and 1.94 hazards ratio for the risk of developing dementia 3–10 years following midlife and late-life insomnia, respectively (71). However, it remains uncertain whether insomnia is one of the causes or a consequence of neurodegenerative processes or a combination of both. Effects of sleep deprivation have mainly been shown to be associated to amyloid deposition, and there are an increasing number of reports referring to co-existing amyloidopathy in PD patients with dementia (72, 73). Whether these patients experienced more or serious insomnia is to our knowledge not yet shown, though investigating a possible association is of interest. In AD, how the amount and quality of sleep affects Aβ aggregation is not fully understood, but animal studies indicate the importance of delaying the onset of this pathology in impacting the time of onset of disease, and such manipulation may be a powerful way to modulate amyloid pathology in the preclinical stages of disease.
Sleep disturbances in young and middle-aged adults may herald the pathological processes leading to α-synucleinopathies. Considering the negative health implications of long-term sleep disruption, they may even potentiate the development of neurodegenerative disease. This might be augmented in some individuals with a genetic predisposition to circadian dysfunction or neurodegeneration, for example genetic variants in circadian clock genes are associated with susceptibility to PD and other neurodegenerative disorders (74–76), and to cognitive impairment in the general elderly population (77). Further genetic and epigenetic factors influencing the aging process, response to treatment, or susceptibility to sleep disorders directly, can also be expected to play a role in modulating sleep disorders and the underlying neurodegenerative processes, and will provide useful insights into the biological basis of these disorders, and potential targets for future intervention therapies.
To establish if and when early treatment of sleep disturbances changes the course of neurodegenerative disease, there is a need for longitudinal population studies of the natural history of the development of sleep disorders and the conversion to α-synucleinopathies. The focus should be on early changes in circadian rhythms, sleep deprivation, EDS and RBD several decades before the manifest occurrence of motor symptoms in PD. Such work will bring us closer to the goal of intervention studies, by revealing the severity and timing of the onset of circadian disturbances in sufferers of PD compared to the occurrence in the otherwise healthy aging population. The enrollment of patients with idiopathic RBD or carriers of mutations in GBA are promising strategies to enrich studies for individuals at risk of converting to PD. Collaborative efforts between cohorts will also hasten progress to understand the implications of maximizing sleep health on the prevalence of PD and α-synucleinopathies in the future generations.
Author Contributions
MG contributed conception of the review. MG and JM-G wrote the first draft of the manuscript. GA wrote sections, and critically reviewed the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. Balkin TJ, Rupp T, Picchioni D, Wesensten NJ. Sleep loss and sleepiness: current issues. Chest (2008) 134:653–60. doi: 10.1378/chest.08-1064
2. Durmer JS, Dinges DF. Neurocognitive consequences of sleep deprivation. Semin Neurol. (2005) 25:117–29. doi: 10.1055/s-2005-867080
3. Jones K, Harrison Y. Frontal lobe function, sleep loss and fragmented sleep. Sleep Med Rev. (2001) 5:463–75. doi: 10.1053/smrv.2001.0203
4. Ellenbogen JM. Cognitive benefits of sleep and their loss due to sleep deprivation. Neurology (2005) 64:E25–7. doi: 10.1212/01.wnl.0000164850.68115.81
5. Stickgold R, Walker MP. Sleep-dependent memory consolidation and reconsolidation. Sleep Med. (2007) 8:331–43. doi: 10.1016/j.sleep.2007.03.011
6. Tononi G, Cirelli C. Sleep and the price of plasticity: from synaptic and cellular homeostasis to memory consolidation and integration. Neuron (2014) 81:12–34. doi: 10.1016/j.neuron.2013.12.025
7. Foley DJ, Monjan AA, Brown SL, Simonsick EM, Wallace RB, Blazer DG. Sleep complaints among elderly persons: an epidemiologic study of three communities. Sleep (1995) 18:425–32. doi: 10.1093/sleep/18.6.425
8. Munch M, Knoblauch V, Blatter K, Schroder C, Schnitzler C, Krauchi K, et al. Age-related attenuation of the evening circadian arousal signal in humans. Neurobiol Aging (2005) 26:1307–19. doi: 10.1016/j.neurobiolaging.2005.03.004
9. Saper CB, Fuller PM, Pedersen NP, Lu J, Scammell TE. Sleep state switching. Neuron (2010) 68:1023–42. doi: 10.1016/j.neuron.2010.11.032
10. Yousaf T, Pagano G, Niccolini F, Politis M. Increased dopaminergic function in the thalamus is associated with excessive daytime sleepiness. Sleep Med. (2018) 43:25–30. doi: 10.1016/j.sleep.2017.11.1137
11. Yousaf T, Pagano G, Niccolini F, Politis M. Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease. J Neurol Sci. (2018) 387:220–27. doi: 10.1016/j.jns.2018.02.032
12. Pagano G, Molloy S, Bain PG, Rabiner EA, Chaudhuri KR, Brooks DJ, et al. Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. Neurology (2016) 87:2451–6. doi: 10.1212/WNL.0000000000003396
13. Claassen DO, Josephs KA, Ahlskog JE, Silber MH, Tippmann-Peikert M, Boeve BF. REM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a century. Neurology (2010) 75:494–9. doi: 10.1212/WNL.0b013e3181ec7fac
14. Pagano G, Ferrara N, Brooks DJ, Pavese N. Age at onset and Parkinson disease phenotype. Neurology (2016) 86:1400–7. doi: 10.1212/WNL.0000000000002461
15. Rajput AH, Voll A, Rajput ML, Robinson CA, Rajput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. Neurology (2009) 73:206–12. doi: 10.1212/WNL.0b013e3181ae7af1
16. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. (2015) 72:863–73. doi: 10.1001/jamaneurol.2015.0703
17. Marras C, Chaudhuri KR. Nonmotor features of Parkinson's disease subtypes. Mov Disord. (2016) 31:1095–102. doi: 10.1002/mds.26510
18. Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. (2016) 15:405–19. doi: 10.1016/S1474-4422(16)00057-0
19. American Academy of Sleep Medicine Board of, International Classification of Sleep Disorders. Darien, IL: American Academy of Sleep Medicine (2014).
20. Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. (2013) 14:744–8. doi: 10.1016/j.sleep.2012.10.009
21. Postuma RB, Pelletier A, Berg D, Gagnon JF, Escudier F, Montplaisir J. Screening for prodromal Parkinson's disease in the general community: a sleep-based approach. Sleep Med. (2016) 21:101–5. doi: 10.1016/j.sleep.2015.12.016
22. Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study. Lancet Neurol. (2017) 16:66–75. doi: 10.1016/S1474-4422(16)30328-3
23. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. (2013) 12:443–53. doi: 10.1016/S1474-4422(13)70056-5
24. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2003) 24:197–211. doi: 10.1016/S0197-4580(02)00065-9
25. Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT. Structural brain alterations associated with rapid eye movement sleep behavior disorder in Parkinson's disease. Sci Rep. (2016) 6:26782. doi: 10.1038/srep26782
26. Stokholm MG, Iranzo A, Ostergaard K, Serradell M, Otto M, Svendsen KB, et al. Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. (2017) 16:789–96. doi: 10.1016/S1474-4422(17)30173-4
27. Gan-Or Z, Mirelman A, Postuma RB, Arnulf I, Bar-Shira A, Dauvilliers Y, et al. GBA mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. Ann Clin Transl Neurol. (2015) 2:941–5. doi: 10.1002/acn3.228
28. Beavan M, McNeill A, Proukakis C, Hughes DA, Mehta A, Schapira AH. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort. JAMA Neurol. (2015) 72:201–8. doi: 10.1001/jamaneurol.2014.2950
29. McNeill A, Duran R, Hughes DA, Mehta A, Schapira AH. A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers. J Neurol Neurosurg Psychiatry (2012) 83:853–4. doi: 10.1136/jnnp-2012-302402
30. Thaler A, Gurevich T, Bar Shira A, Gana Weisz M, Ash E, Shiner T, et al. A “dose” effect of mutations in the GBA gene on Parkinson's disease phenotype. Parkinsonism Relat Disord. (2017) 36:47–51. doi: 10.1016/j.parkreldis.2016.12.014
31. Jesus S, Huertas I, Bernal-Bernal I, Bonilla-Toribio M, Caceres-Redondo MT, Vargas-Gonzalez L, et al. GBA variants influence motor and non-motor features of Parkinson's disease. PLoS ONE (2016) 11:e0167749. doi: 10.1371/journal.pone.0167749
32. Papadimitriou D, Antonelou R, Miligkos M, Maniati M, Papagiannakis N, Bostantjopoulou S, et al. Motor and nonmotor features of carriers of the p.A53T alpha-synuclein mutation: a Longitudinal Study. Mov Disord. (2016) 31:1226–30. doi: 10.1002/mds.26615
33. Fernandez-Santiago R, Iranzo A, Gaig C, Serradell M, Fernandez M, Pastor P, et al. MAPT association with REM sleep behavior disorder. Neurol Genet. (2017) 3:e131. doi: 10.1212/NXG.0000000000000131
34. Toffoli M, Dreussi E, Cecchin E, Valente M, Sanvilli N, Montico M, et al. SNCA 3'UTR genetic variants in patients with Parkinson's disease and REM sleep behavior disorder. Neurol Sci. (2017) 38:1233–40. doi: 10.1007/s10072-017-2945-2
35. Li Y, Kang W, Zhang L, Zhou L, Niu M, Liu J. Hyposmia is associated with RBD for PD patients with variants of SNCA. Front Aging Neurosci. (2017) 9:303. doi: 10.3389/fnagi.2017.00303
36. Gan-Or Z, Girard SL, Noreau A, Leblond CS, Gagnon JF, Arnulf I, et al. Parkinson's disease genetic loci in rapid eye movement sleep behavior disorder. J Mol Neurosci. (2015) 56:617–22. doi: 10.1007/s12031-015-0569-7
37. Trenkwalder C, Kohnen R, Hogl B, Metta V, Sixel-Doring F, Frauscher B, et al. Parkinson's disease sleep scale–validation of the revised version PDSS-2. Mov Disord. (2011) 26:644–52. doi: 10.1002/mds.23476
38. Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP. Excessive daytime sleepiness in Parkinson disease: is it the drugs or the disease? Neurology (2006) 67:853–8. doi: 10.1212/01.wnl.0000233980.25978.9d
39. Jaussent I, Bouyer J, Ancelin ML, Berr C, Foubert-Samier A, Ritchie K, et al. Excessive sleepiness is predictive of cognitive decline in the elderly. Sleep (2012) 35:1201–7. doi: 10.5665/sleep.2070
40. Foley D, Monjan A, Masaki K, Ross W, Havlik R, White L, et al. Daytime sleepiness is associated with 3-year incident dementia and cognitive decline in older Japanese-American men. J Am Geriatr Soc. (2001):49:1628–32. doi: 10.1111/j.1532-5415.2001.49271.x
41. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology (2005) 65:1442–6. doi: 10.1212/01.wnl.0000183056.89590.0d
42. Gao J, Huang X, Park Y, Hollenbeck A, Blair A, Schatzkin A, et al. Daytime napping, nighttime sleeping, and Parkinson disease. Am J Epidemiol. (2011) 173:1032–8. doi: 10.1093/aje/kwq478
43. Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD. Development of excessive daytime sleepiness in early Parkinson disease. Neurology (2015) 85:162–8. doi: 10.1212/WNL.0000000000001737
44. Duncan GW, Khoo TK, Yarnall AJ, O'Brien JT, Coleman SY, Brooks DJ, et al. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov Disord. (2014) 29:195–202. doi: 10.1002/mds.25664
45. Giganti F, Ramat S, Zilli I, Guidi S, Raglione LM, Sorbi S et al. Daytime course of sleepiness in de novo Parkinson's disease patients. J Sleep Res. (2013) 22:197–200. doi: 10.1111/jsr.12000
46. Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA. Excessive daytime sleepiness and its risk factors in incident Parkinson's disease. J Neurol Neurosurg Psychiatry (2013) 84:233–4. doi: 10.1136/jnnp-2012-304097
47. Mylius V, Moller JC, Strauch K, Oertel WH, Stiasny-Kolster K. No significance of the COMT val158met polymorphism in restless legs syndrome. Neurosci Lett. (2010) 473:151–4. doi: 10.1016/j.neulet.2010.02.042
48. Gottlieb DJ, O'Connor GT, Wilk JB. Genome-wide association of sleep and circadian phenotypes. BMC Med Genet. (2007) 8(Suppl 1):S9. doi: 10.1186/1471-2350-8-S1-S9
49. Kaut O, Schmitt I, Tost J, Busato F, Liu Y, Hofmann P, et al. Epigenome-wide DNA methylation analysis in siblings and monozygotic twins discordant for sporadic Parkinson's disease revealed different epigenetic patterns in peripheral blood mononuclear cells. Neurogenetics (2017) 18:7–22. doi: 10.1007/s10048-016-0497-x
50. Yang L, Calingasan NY, Lorenzo BJ, Beal MF. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol. (2008) 211:311–4. doi: 10.1016/j.expneurol.2007.02.010
51. Bate C, Williams A. cAMP-Inhibits Cytoplasmic Phospholipase A(2) and protects neurons against amyloid-beta-induced synapse damage. Biology (2015) 4:591–606. doi: 10.3390/biology4030591
52. Kreutzmann JC, Havekes R, Abel T, Meerlo P. Sleep deprivation and hippocampal vulnerability: changes in neuronal plasticity, neurogenesis and cognitive function. Neuroscience (2015) 309:173–90. doi: 10.1016/j.neuroscience.2015.04.053
53. Joo EY, Kim H, Suh S, Hong SB. Hippocampal substructural vulnerability to sleep disturbance and cognitive impairment in patients with chronic primary insomnia: magnetic resonance imaging morphometry. Sleep (2014) 37:1189–98. doi: 10.5665/sleep.3836
54. Bellesi M, de Vivo L, Chini M, Gilli F, Tononi G, Cirelli C. Sleep loss promotes astrocytic phagocytosis and microglial activation in mouse cerebral cortex. J Neurosci. (2017) 37:5263–73. doi: 10.1523/JNEUROSCI.3981-16.2017
55. Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science (2013) 342:373–7. doi: 10.1126/science.1241224
56. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 326:1005–7. doi: 10.1126/science.1180962
57. Ju YS, Ooms SJ, Sutphen C, Macauley SL, Zangrilli MA, Jerome G, et al. Slow wave sleep disruption increases cerebrospinal fluid amyloid-beta levels. Brain (2017) 140:2104–11. doi: 10.1093/brain/awx148
58. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology (2008) 71:903–10. doi: 10.1212/01.wnl.0000326146.60732.d6
59. Archer SN, Laing EE, Moller-Levet CS, van der Veen DR, Bucca G, Lazar AS, et al. Mistimed sleep disrupts circadian regulation of the human transcriptome. Proc Natl Acad Sci USA. (2014) 111:E682–91. doi: 10.1073/pnas.1316335111
60. Cai Y, Liu S, Sothern RB, Xu S, Chan P. Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol. (2010) 17:550–4. doi: 10.1111/j.1468-1331.2009.02848.x
61. Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, et al. Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol. (2014) 71:589–95. doi: 10.1001/jamaneurol.2014.65
62. Ding H, Liu S, Yuan Y, Lin Q, Chan P, Cai Y. Decreased expression of Bmal2 in patients with Parkinson's disease. Neurosci Lett. (2011) 499:186–8. doi: 10.1016/j.neulet.2011.05.058
63. Lin Q, Ding H, Zheng Z, Gu Z, Ma J, Chen L, et al. Promoter methylation analysis of seven clock genes in Parkinson's disease. Neurosci Lett. (2012) 507:147–50. doi: 10.1016/j.neulet.2011.12.007
64. Liu HC, Hu CJ, Tang YC, Chang JG. A pilot study for circadian gene disturbance in dementia patients. Neurosci Lett. (2008) 435:229–33. doi: 10.1016/j.neulet.2008.02.041
65. Mendoza J, Challet E. Circadian insights into dopamine mechanisms. Neuroscience (2014) 282:230–42. doi: 10.1016/j.neuroscience.2014.07.081
66. Sleipness EP, Sorg BA, Jansen HT. Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: dependence on the suprachiasmatic nucleus. Brain Res. (2007) 1129:34–42. doi: 10.1016/j.brainres.2006.10.063
67. Imbesi M, Yildiz S, Dirim Arslan A, Sharma R, Manev H, Uz T. Dopamine receptor-mediated regulation of neuronal “clock” gene expression. Neuroscience (2009) 158:537–44. doi: 10.1016/j.neuroscience.2008.10.044
68. Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M, Robinson B, et al. Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci. (2010) 30:14046–58. doi: 10.1523/JNEUROSCI.2128-10.2010
69. Pallier PN, Maywood ES, Zheng Z, Chesham JE, Inyushkin AN, Dyball R, et al. Pharmacological imposition of sleep slows cognitive decline and reverses dysregulation of circadian gene expression in a transgenic mouse model of Huntington's disease. J Neurosci. (2007) 27:7869–78. doi: 10.1523/JNEUROSCI.0649-07.2007
70. Wang HB, Loh DH, Whittaker DS, Cutler T, Howland D, Colwell CS. Time-restricted feeding improves circadian dysfunction as well as motor symptoms in the Q175 mouse model of Huntington's disease. eNeuro (2018) 5:ENEURO.0431-17.2017. doi: 10.1523/ENEURO.0431-17.2017
71. Sindi S, Johansson L, Skoog J, Mattsson AD, Sjoberg L, Wang HX, et al. Sleep disturbances and later cognitive status: a multi-centre study. Sleep Med. (2018) 52:26–33. doi: 10.1016/j.sleep.2017.11.1149
72. Irwin DJ, White MT, Toledo JB, Xie SX, Robinson JL, Van Deerlin V, et al. Neuropathologic substrates of Parkinson disease dementia. Ann Neurol. (2012) 72:587–98. doi: 10.1002/ana.23659
73. Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Muller ML, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. Mov Disord. (2015) 30:928–35. doi: 10.1002/mds.26191
74. Gu Z, Wang B, Zhang YB, Ding H, Zhang Y, Yu J, et al. Association of ARNTL and PER1 genes with Parkinson's disease: a case-control study of Han Chinese. Sci Rep. (2015) 5:15891. doi: 10.1038/srep15891
75. Chen Q, Huang CQ, Hu XY, Li SB, Zhang XM. Functional CLOCK gene rs1554483 G/C polymorphism is associated with susceptibility to Alzheimer's disease in the Chinese population. J Int Med Res. (2013) 41:340–6. doi: 10.1177/0300060513476430
76. Lou F, Li M, Ren Y, Luo XG, Liu N, Li X. CLOCK rs1801260 polymorphism is associated with susceptibility to Parkinson's disease in a Chinese population. Neurosci Bull. (2017) 33:734–6. doi: 10.1007/s12264-017-0167-5
Keywords: early Parkinson's disease, sleep, genetics, EDS, RBD
Citation: Gjerstad MD, Alves G and Maple-Grødem J (2018) Excessive Daytime Sleepiness and REM Sleep Behavior Disorders in Parkinson's Disease: A Narrative Review on Early Intervention With Implications to Neuroprotection. Front. Neurol. 9:961. doi: 10.3389/fneur.2018.00961
Received: 31 January 2018; Accepted: 25 October 2018;
Published: 14 November 2018.
Edited by:
Marina Bentivoglio, Università degli Studi di Verona, ItalyReviewed by:
Gennaro Pagano, King's College London, United KingdomErik K. St. Louis, Mayo Clinic College of Medicine & Science, United States
Copyright © 2018 Gjerstad, Alves and Maple-Grødem. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michaela D. Gjerstad, gjmi@sus.no